Should Myfortic Be Stopped When Lupus Nephritis Receives Pulse Dose Steroids?
No, Myfortic (mycophenolate sodium) should NOT be discontinued when administering pulse-dose intravenous steroids for active lupus nephritis—these therapies are designed to work together as combination treatment.
Rationale Based on Current Guidelines
The most recent EULAR 2025 guidelines explicitly recommend that IV pulse methylprednisolone be given in combination with mycophenolate (which includes both mycophenolate mofetil and mycophenolate sodium formulations like Myfortic) for active lupus nephritis 1. The guideline states that for patients with active lupus nephritis, IV pulse methylprednisolone is recommended, followed by oral glucocorticoids, while simultaneously continuing mycophenolate therapy 1.
The KDIGO 2024 guidelines similarly recommend that patients with active Class III or IV lupus nephritis be treated with glucocorticoids plus mycophenolic acid analogs as one of the primary treatment options 2. There is no recommendation to interrupt mycophenolate when administering pulse steroids.
The Treatment Algorithm
For Active Lupus Nephritis:
Initiate IV pulse methylprednisolone (typically 0.25-0.5 g/day for up to 3 days) 1
Continue Myfortic without interruption throughout pulse steroid administration
Follow with oral prednisone (gradually tapered to ≤5 mg/day by 4-6 months) 1
Maintain mycophenolate therapy for at least 3 years following renal response 1
Why These Therapies Work Together
The combination approach targets different immunologic mechanisms:
- Pulse steroids provide rapid anti-inflammatory effects through both genomic and non-genomic mechanisms 3
- Mycophenolate provides sustained immunosuppression by inhibiting lymphocyte proliferation
- Together, they achieve superior disease control compared to either agent alone
The EULAR guidelines specifically recommend combination therapy as the preferred approach, listing mycophenolate with belimumab, mycophenolate with calcineurin inhibitors, or mycophenolate with obinutuzumab as first-line options 1, 2. This underscores that mycophenolate is meant to be continued alongside steroid therapy, not interrupted.
Important Caveats
When to Consider Dose Adjustment (Not Discontinuation):
The FDA label for mycophenolate products indicates that dose interruption or reduction should only be considered if 4:
- Severe neutropenia develops (ANC <1.3 x 10³/µL)
- Severe gastrointestinal complications occur (bleeding, perforation)
- Signs of infection emerge requiring diagnostic workup
Even in these scenarios, the recommendation is dose adjustment or temporary interruption—not permanent discontinuation—unless the patient cannot tolerate the medication at all.
Monitoring During Combined Therapy:
When administering pulse steroids with Myfortic, monitor 4:
- Complete blood counts weekly for the first month, then twice monthly for months 2-3
- Signs of infection (increased risk with dual immunosuppression)
- Renal function and proteinuria to assess treatment response 1
Common Pitfall to Avoid
Do not confuse "pulse steroids" with a reason to stop other immunosuppressants. The pulse steroid is an addition to the regimen, not a replacement. Stopping mycophenolate when giving pulse steroids would leave the patient with inadequate long-term immunosuppression once the steroid pulse effect wears off, potentially leading to disease flare.
The treatment targets require sustained therapy: achieving ≥25% reduction in proteinuria by 3 months and ≥50% by 6 months 1, which cannot be accomplished with pulse steroids alone.
Evidence Quality Note
The recommendation to continue mycophenolate with pulse steroids is based on Level 1A/1B evidence from multiple randomized controlled trials 1, 2 and represents the highest quality evidence available. The 2025 EULAR guidelines achieved 100% expert consensus on this treatment approach 1.